AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02989480 — intervention group
Intervention type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI
Study NCT01500863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: single shot of 6500 IU hCG s.c. at the time of triggering
Study NCT01500863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: single shot of 0.2mg triptorelin s.c. at the time of triggering
Study NCT01500863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin, estradiol valerate, micronized vaginal progesterone
Description: 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
Study NCT01500863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin, hCG
Description: single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
Study NCT04626453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-month home moderate-intensity exercise
Description: The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
Study NCT04144478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based education
Description: Web based education
Study NCT02067273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Study NCT04684004 — intervention group
Intervention type: OTHER
Intervention: To report number of HF events and deaths
Description: In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
Study NCT02374489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
Study NCT02053935 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dopamine
Description: Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
Study NCT03265418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioXmark liquid fiducial markers
Description: Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
Study NCT03265418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy.
Study NCT03265418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery or wait-and-see
Description: As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol.
Study NCT03422939 — intervention group
Intervention type: OTHER
Intervention: there was no intervention, only separate analyses
Description: We only conducted separate analyses to see if responses differed according to level of experience.
Study NCT03322930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rod sensitivity
Description: diagnostic test for rod loss in central retina
Study NCT03244501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active tSMS
Description: A cylindrical neodymium magnet is placed above the scalp.
Study NCT03244501 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tSMS
Description: A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
Study NCT01595386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
Study NCT01595386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
Study NCT04136457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Subjects perform a period of endurance training
Study NCT04136457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Subjects perform a period of resistance training
Study NCT04136457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint training
Description: Subjects perform a period of sprint training
Study NCT02730117 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dialysis with continuous renal replacement therapy
Description: Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
Study NCT02730117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialysis with continuous renal replacement therapy
Description: Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
Study NCT02730117 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical ventilator
Description: Invasive or noninvasive form of respiratory support
Study NCT02730117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilator
Description: Invasive or noninvasive form of respiratory support
Study NCT01500863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin, hCG
Description: Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
Study NCT01500863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin, recombinant LH
Description: 300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
Study NCT01199497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1
Description: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
Study NCT01199497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 2
Description: placebo
Study NCT03641794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DN1406131
Description: IDO1 and TDO2 inhibitor
Study NCT03641794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01341145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
Study NCT03205189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison between pre-operative prescription and post-operative prescription
Description: The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
Study NCT02569333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
Study NCT03189810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
Study NCT03189810 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
Study NCT03189810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Counselling Session
Description: In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
Study NCT03189810 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Weekly Counselling Session
Description: In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
Study NCT01379430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP followed by MVA ME-TRAP
Description: AdCh63 ME-TRAP 1x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intramuscularly
Study NCT01341145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: 12-week progressive muscle relaxation program (active control)
Study NCT00714649 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cetuximab
Description: Cetuximab 250mg/m²/week IV before surgery till surgery
Study NCT02730117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Bacterial Agents
Description: Antibacterial agents deemed appropriate by physicians in the ICU
Study NCT02730117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Bacterial Agents
Description: Antibacterial agents deemed appropriate by physicians in the ICU
Study NCT02730117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasopressors
Description: Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
Study NCT02730117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressors
Description: Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
Study NCT04008654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERAS Protocol
Description: Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results
Study NCT04008654 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care
Description: This group of patients will not receive the specific ERAS protocol but will receive conventional care.
Study NCT02872207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987516 (Y65-122)
Description: 5 µL in one eye
Study NCT02872207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987516 (Y65-118)
Description: 5 µL in one eye
Study NCT02872207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: 5 uL in other eye
Study NCT01379430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP followed by MVA ME-TRAP
Description: AdCh63 ME-TRAP 5x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intradermal
Study NCT01383213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
Study NCT01383213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Description: patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
Study NCT00174928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
Study NCT00174928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
Study NCT02971735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile technology of e-learning (M-TEL)
Description: UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
Study NCT02971735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile technology of e-learning (M-TEL)
Description: UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
Study NCT01874054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
Study NCT01874054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 90 mg/m2 on Days 1 and 2 of 3-week cycles
Study NCT02988843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
Study NCT02988843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg every 21 days
Study NCT00133471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/H9N2 vaccine
Description: A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
Study NCT00133471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 adjuvant
Description: MF59 adjuvant is an oil-in-water emulsion.
Study NCT00592215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental (mifepristone and misoprostol)
Description: Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
Study NCT05683769 — intervention group
Intervention type: GENETIC
Intervention: miRNA
Description: Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis
Study NCT00536562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Cardiac Rehabilitation (CR)
Description: 6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition \& psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
Study NCT01114256 — intervention group
Intervention type: PROCEDURE
Intervention: FNA Biopsy
Study NCT04081974 — intervention group
Intervention type: OTHER
Intervention: Distal leg perfusion
Description: On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
Study NCT01957930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified insulin treatment
Description: The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
Study NCT01957930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
Study NCT01605162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
Study NCT01605162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7016
Description: E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle.
Study NCT04154735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
Study NCT04154735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A medication used as chemotherapy and to suppress the immune system
Study NCT04154735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Study NCT04154735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
Study NCT04154735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
Study NCT04154735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
Study NCT04154735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
Study NCT03166384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrosurgical bipolar sealing devices
Description: Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
Study NCT03166384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional suture and tie
Description: the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
Study NCT02641808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follicular flushing
Description: Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.